1. Home
  2. SNY
  3. SNY News

Latest Sanofi ADS (SNY) News on December 22, 2024

Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS
SNY

TipRanks

18 hours ago

Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS

Why Cytokinetics Stock Was a Nearly 5% Winner Today
SNY

Motley Fool

a day ago

Why Cytokinetics Stock Was a Nearly 5% Winner Today

Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
SNY

Zacks

2 days ago

Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals

SNY

MT Newswires

2 days ago

Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
SNY

GlobeNewswire

3 days ago

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
SNY

Zacks

4 days ago

SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study

Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?
SNY

Zacks

4 days ago

Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?

Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial
SNY

Clinical Trials Arena

4 days ago

Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trial

SNY

Morningstar Research

4 days ago

Analyst Report: Sanofi

Teva and Sanofi jump on experimental bowel disease drug success
SNY

Yahoo Finance Video

4 days ago

Teva and Sanofi jump on experimental bowel disease drug success

Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug
SNY

Investor's Business Daily

4 days ago

Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug

Teva, Sanofi Say Inflammatory Bowel Disease Drug Study Meets Primary Endpoints
SNY

MT Newswires

4 days ago

Teva, Sanofi Say Inflammatory Bowel Disease Drug Study Meets Primary Endpoints

Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's
SNY

Investopedia

4 days ago

Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's

SNY

MT Newswires

5 days ago

Update: Teva, Sanofi Shares Jump as Phase 2B Duvakitug Study Meets Primary Endpoints in Inflammatory Bowel Disease

Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial Expectations
SNY

GuruFocus.com

5 days ago

Teva Stock Soars 19% as Game-Changing IBD Drug Duvakitug Crushes Trial Expectations

Teva, Cloudflare, Sanofi: Trending Tickers
SNY

Yahoo Finance Video

5 days ago

Teva, Cloudflare, Sanofi: Trending Tickers

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
SNY

The Wall Street Journal

5 days ago

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug
SNY

Investor's Business Daily

5 days ago

Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug

Teva Shares Soar on Early Bowel Disease Drug Data
SNY

Barrons.com

5 days ago

Teva Shares Soar on Early Bowel Disease Drug Data

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
SNY

Benzinga

5 days ago

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?

SNY

MT Newswires

5 days ago

Teva, Sanofi Say Phase 2B Duvakitug Study Meets Primary Endpoints in Inflammatory Bowel Disease

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
SNY

GlobeNewswire

5 days ago

Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease

SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS
SNY

Zacks

9 days ago

SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS

SNY

MT Newswires

9 days ago

Novavax Hits First Milestone in Sanofi Partnership, Secures $50 Million Payment

Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
SNY

GlobeNewswire

9 days ago

Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis

Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
SNY

Reuters

9 days ago

Gilead appoints Sanofi official Dietmar Berger as next chief medical officer

Sanofi’s combo vaccines gain FDA fast track designation
SNY

Pharmaceutical Technology

10 days ago

Sanofi’s combo vaccines gain FDA fast track designation

FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates
SNY

Zacks

11 days ago

FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates

NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines
SNY

Zacks

11 days ago

NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines

Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
SNY

GlobeNewswire

11 days ago

Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US

RSV prophylactic market to reach $6.2bn in 8MM by 2030
SNY

Pharmaceutical Technology

12 days ago

RSV prophylactic market to reach $6.2bn in 8MM by 2030

Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
SNY

GlobeNewswire

12 days ago

Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients

Sanofi’s Phase III trial of rilzabrutinib for thrombocytopenia meets endpoint
SNY

Clinical Trials Arena

13 days ago

Sanofi’s Phase III trial of rilzabrutinib for thrombocytopenia meets endpoint

Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
SNY

GlobeNewswire

15 days ago

Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP

Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
SNY

Zacks

16 days ago

Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?

Denali Starts Dosing in Phase II Parkinson's Disease Study
SNY

Zacks

16 days ago

Denali Starts Dosing in Phase II Parkinson's Disease Study

Press Release: Availability of the revised financial statements for Sanofi excluding Opella
SNY

GlobeNewswire

16 days ago

Press Release: Availability of the revised financial statements for Sanofi excluding Opella

Novavax to Sell Czech Manufacturing Plant to Novo Nordisk for $200M
SNY

Zacks

17 days ago

Novavax to Sell Czech Manufacturing Plant to Novo Nordisk for $200M

Trump 2.0 could see a rise in biopharmaceutical M&A deals
SNY

Pharmaceutical Technology

18 days ago

Trump 2.0 could see a rise in biopharmaceutical M&A deals

China welcomes new US$1 billion Sanofi project in Beijing
SNY

South China Morning Post

19 days ago

China welcomes new US$1 billion Sanofi project in Beijing

Sanofi to Invest $1.05 Billion in New Insulin Manufacturing Base in China
SNY

The Wall Street Journal

19 days ago

Sanofi to Invest $1.05 Billion in New Insulin Manufacturing Base in China

SNY

Morningstar Research

20 days ago

Analyst Report: Sanofi

Sanofi announces its biggest China investment deal amid China-EU trade tensions
SNY

Reuters

20 days ago

Sanofi announces its biggest China investment deal amid China-EU trade tensions

Why Sanofi (SNY) Is One of the Best ADR Stocks to Invest in?
SNY

Insider Monkey

22 days ago

Why Sanofi (SNY) Is One of the Best ADR Stocks to Invest in?

Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate
SNY

Fortune

23 days ago

Sanofi’s chief digital officer says remote work means employees lose the ‘serendipity’ needed to innovate

Sanofi CEO Paul Hudson takes inspiration from ‘Fight Club’ to get his team hooked on AI
SNY

Fortune

25 days ago

Sanofi CEO Paul Hudson takes inspiration from ‘Fight Club’ to get his team hooked on AI

Sanofi joins J&J, Eli Lilly in proposing 340B rebate model
SNY

Healthcare Dive

a month ago

Sanofi joins J&J, Eli Lilly in proposing 340B rebate model

SNY

Zacks Small Cap Research

a month ago

MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement…

Trump’s presidency return: boom or bust for biopharmaceutical deal activity?
SNY

Pharmaceutical Technology

a month ago

Trump’s presidency return: boom or bust for biopharmaceutical deal activity?

Sanofi plans to change hospital drug-discount program
SNY

Reuters

a month ago

Sanofi plans to change hospital drug-discount program

SNY

MT Newswires

a month ago

Market Chatter: Sanofi Plans Drug Discount Policy Restriction

Here’s What Drove Sanofi’s (SNY) Earnings
SNY

Insider Monkey

a month ago

Here’s What Drove Sanofi’s (SNY) Earnings

Sanofi: Information concerning the total number of voting rights and shares - October 2024
SNY

GlobeNewswire

a month ago

Sanofi: Information concerning the total number of voting rights and shares - October 2024

FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
SNY

Zacks

a month ago

FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria

SNY

Argus Research

a month ago

Weekly Stock List

SNY

Morningstar Research

a month ago

Analyst Report: Sanofi

How analysts are reacting to RFK Jr. as Trump's HHS pick
SNY

Yahoo Finance Video

a month ago

How analysts are reacting to RFK Jr. as Trump's HHS pick

Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell?
SNY

Investor's Business Daily

a month ago

Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell?

FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
SNY

Pharmaceutical Technology

a month ago

FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria

Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.
SNY

Yahoo Finance

a month ago

Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.

Trump’s RFK Jr. Pick Weighs on Vaccine Makers
SNY

The Wall Street Journal

a month ago

Trump’s RFK Jr. Pick Weighs on Vaccine Makers

Stocks to Watch Friday: Alibaba, Domino's, Palantir, Ulta Beauty
SNY

The Wall Street Journal

a month ago

Stocks to Watch Friday: Alibaba, Domino's, Palantir, Ulta Beauty

RFK Jr. News Hits Global Pharma Stocks
SNY

The Wall Street Journal

a month ago

RFK Jr. News Hits Global Pharma Stocks

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department
SNY

The Wall Street Journal

a month ago

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma
SNY

Pharmaceutical Technology

a month ago

EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma

SNY

MT Newswires

a month ago

Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Application for Skin Disease Treatment

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
SNY

GlobeNewswire

a month ago

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Top Analyst Reports for UnitedHealth, Bank of America & SAP
SNY

Zacks

a month ago

Top Analyst Reports for UnitedHealth, Bank of America & SAP

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
SNY

Benzinga

a month ago

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease

Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut
SNY

Zacks

a month ago

Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut

Novavax Inc (NVAX) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...
SNY

GuruFocus.com

a month ago

Novavax Inc (NVAX) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...

Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals
SNY

Yahoo Finance

a month ago

Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals

Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
SNY

Reuters

a month ago

Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales

SNY

Argus Research

a month ago

Daily Spotlight: A Range of Options Among Sovereign Debt Yields

SNY

GuruFocus.com

a month ago

Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
SNY

Zacks

a month ago

Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging

SNY

Morningstar Research

a month ago

Analyst Report: Sanofi

Advent Mulls €5 Billion Sale of Generic Drugmaker Zentiva
SNY

Bloomberg

a month ago

Advent Mulls €5 Billion Sale of Generic Drugmaker Zentiva

EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
SNY

Pharmaceutical Technology

a month ago

EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients

SNY

MT Newswires

2 months ago

Sanofi, Regeneron Receive European Pediatric Approval for Throat Disease Treatment

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
SNY

GlobeNewswire

2 months ago

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
SNY

GlobeNewswire

2 months ago

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...
SNY

GuruFocus.com

2 months ago

Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...

Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
SNY

Zacks

2 months ago

Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus

Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...
SNY

GuruFocus.com

2 months ago

Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...

REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
SNY

Zacks

2 months ago

REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales

SNY

Thomson Reuters StreetEvents

2 months ago

Q3 2024 BioMarin Pharmaceutical Inc Earnings Call

SNY

MT Newswires

2 months ago

Sanofi Partners with SandboxAQ on AI-Driven Drug Discovery

Beyfortus® immunization to protect infants from RSV has begun
SNY

CNW Group

2 months ago

Beyfortus® immunization to protect infants from RSV has begun

Regeneron to Report Q3 Earnings: What's in the Offing?
SNY

Zacks

2 months ago

Regeneron to Report Q3 Earnings: What's in the Offing?

SNY

Argus Research

2 months ago

Market Digest: SNY, CME, HOG, PCAR, LEA, VLTO

SNY

Argus Research

2 months ago

Analyst Report: Sanofi SA

Sanofi SA (SNY) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Advances
SNY

GuruFocus.com

2 months ago

Sanofi SA (SNY) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Advances

SNY

Morningstar Research

2 months ago

Analyst Report: Sanofi

Why Sanofi Stock Flew Higher on Friday
SNY

Motley Fool

2 months ago

Why Sanofi Stock Flew Higher on Friday

Sanofi (SNY) Q3 2024 Earnings Call Transcript
SNY

Motley Fool

2 months ago

Sanofi (SNY) Q3 2024 Earnings Call Transcript

Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News
SNY

Zacks

2 months ago

Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News

Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
SNY

Benzinga

2 months ago

Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent

Sanofi Shocks the Market: Massive Q3 Surge, Game-Changing Moves, and Bold Divestment Plans
SNY

GuruFocus.com

2 months ago

Sanofi Shocks the Market: Massive Q3 Surge, Game-Changing Moves, and Bold Divestment Plans

Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales
SNY

Zacks

2 months ago

Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales

Share on Social Networks: